Patents by Inventor Tarja Ahola
Tarja Ahola has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11255861Abstract: The present invention relates to a method for determining risk of preterm birth (PTB) in a pregnant individual. The method comprises measuring in a biological sample obtained from the pregnant individual, levels of biomarkers AFP and free hCGbeta, and at least one biomarker selected from FSTL3, sTNFR1, PIGF2, Activin A, uE3 and sP-selectin and optionally cervical length; or levels of biomarkers AFP and free hCGbeta and cervical length, and determining a relative risk of the pregnant individual developing PTB. The invention relates also to a kit, apparatus and system for predicting risk of PTB.Type: GrantFiled: August 27, 2019Date of Patent: February 22, 2022Assignee: Wallac OyInventors: Pertti Hurskainen, Heikki Kouru, Mikko Sairanen, Tarja Ahola, Teemu Korpimäki
-
Patent number: 10656163Abstract: The present description relates to a method for determining the risk of a pregnant woman with chronic hypertension developing early or late onset pre-eclampsia. The present description provides methods useful for determining risk that a pregnant individual with chronic hypertension will develop an early pre-eclampsia or late pre-eclampsia. Useful combination of biochemical markers including PlGF and sP-Selectin and related clinical population studies are described herein.Type: GrantFiled: September 1, 2015Date of Patent: May 19, 2020Assignee: Wallac OyInventors: Tarja Ahola, Heikki Kouru, Mikko Sairanen
-
Publication number: 20200033354Abstract: The present invention relates to a method for determining risk of preterm birth (PTB) in a pregnant individual. The method comprises measuring in a biological sample obtained from the pregnant individual, levels of biomarkers AFP and free hCGbeta, and at least one biomarker selected from FSTL3, sTNFR1, PIGF2, Activin A, uE3 and sP-selectin and optionally cervical length; or levels of biomarkers AFP and free hCGbeta and cervical length, and determining a relative risk of the pregnant individual developing PTB. The invention relates also to a kit, apparatus and system for predicting risk of PTB.Type: ApplicationFiled: August 27, 2019Publication date: January 30, 2020Applicant: Wallac OyInventors: Pertti HURSKAINEN, Heikki KOURU, Mikko SAIRANEN, Tarja AHOLA, Teemu KORPIMÄKI
-
Patent number: 10444247Abstract: The present invention relates to a method for determining risk of preterm birth (PTB) in a pregnant individual. The method comprises measuring in a biological sample obtained from the pregnant individual, levels of biomarkers AFP and free hCGbeta, and at least one biomarker selected from FSTL3, sTNR1, P1GF2, Activin A, Ue3 and sP-selectin and optionally cervical length; or levels of biomarkers AFP and free hCGbeta and cervical length, and determining a relative risk of the pregnant individual developing PTB. The invention relates also to a kit, apparatus and system for predicting risk of PTB.Type: GrantFiled: September 11, 2015Date of Patent: October 15, 2019Assignee: Wallac OyInventors: Pertti Hurskainen, Heikki Kouru, Mikko Sairanen, Tarja Ahola, Teemu Korpimäki
-
Publication number: 20170285041Abstract: The present description relates to a method for determining the risk of a pregnant woman with chronic hypertension developing early or late onset pre-eclampsia. The present description provides methods useful for determining risk that a pregnant individual with chronic hypertension will develop an early pre-eclampsia or late pre-eclampsia. Useful combination of biochemical markers including PlGF and sP-Selectin and related clinical population studies are described herein.Type: ApplicationFiled: September 1, 2015Publication date: October 5, 2017Applicant: Wallac OyInventors: Tarja Ahola, Heikki Kouru, Mikko Sairanen
-
Publication number: 20170261511Abstract: The present invention relates to a method for determining risk of preterm birth (PTB) in a pregnant individual. The method comprises measuring in a biological sample obtained from the pregnant individual, levels of biomarkers AFP and free hCG-beta, and at least one biomarker selected from FSTL3, sTNR1, P1GF2, Activin A, Ue3 and sP-selectin and optionally cervical length; or levels of biomarkers AFP and free hCGbeta and cervical length, and determining a relative risk of the pregnant individual developing PTB. The invention relates also to a kit, apparatus and system for predicting risk of PTB.Type: ApplicationFiled: September 11, 2015Publication date: September 14, 2017Applicant: Wallac OyInventors: Pertti HURSKAINEN, Heikki KOURU, Mikko SAIRANEN, Tarja AHOLA, Teemu KORPIMAKI
-
Publication number: 20160305950Abstract: The disclosure relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual has for developing pre-eclampsia based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers. The disclosure also relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual is carrying a fetus having a chromosomal abnormality based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers.Type: ApplicationFiled: November 13, 2015Publication date: October 20, 2016Inventors: Howard Cuckle, Kypros Nicolaides, Tarja Ahola, Leona Poon
-
Patent number: 9250251Abstract: The present description relates to a method for determining the risk of a pregnant woman developing a hypertensive disorder, more specifically gestational hyper-tension or late onset preeclampsia. The present description provides methods useful for determining risk that a pregnant individual will develop a hypertensive disorder or condition of pregnancy, such as gestational hypertension, early preeclampsia, late preeclampsia and related disorders. Several useful combinations of biochemical markers and related clinical population studies are described herein. Additionally, it is proposed herein that certain sets of biochemical markers can be used to determine risk of multiple hypertensive disorders in a single screen. The biochemical markers are PlGF, Activin A and optionally P-Selectin.Type: GrantFiled: April 23, 2010Date of Patent: February 2, 2016Assignee: WALLAC OYInventors: Kypros Nicolaides, Tarja Ahola
-
Publication number: 20140113319Abstract: The disclosure relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual has for developing pre-eclampsia based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers. The disclosure also relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual is carrying a fetus having a chromosomal abnormality based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers.Type: ApplicationFiled: December 31, 2013Publication date: April 24, 2014Applicants: PerkinElmer Health Sciences, Inc., Fetal Medicine Foundation, The, Wallac OyInventors: Howard Cuckle, Kypros Nicolaides, Tarja Ahola, Leona Poon
-
Patent number: 8647832Abstract: The disclosure relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual has for developing pre-eclampsia based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers. The disclosure also relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual is carrying a fetus having a chromosomal abnormality based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers.Type: GrantFiled: January 26, 2009Date of Patent: February 11, 2014Assignees: PerkinElmer Health Sciences, Inc., Wallac Oy, The Fetal Medicine FoundationInventors: Howard Cuckle, Kypros Nicolaides, Tarja Ahola, Leona Poon
-
Publication number: 20130344503Abstract: The disclosure relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual has for developing pre-eclampsia based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers. The disclosure also relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual is carrying a fetus having a chromosomal abnormality based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers.Type: ApplicationFiled: July 18, 2013Publication date: December 26, 2013Applicants: The Fetal Medicine Foundation, Wallac Oy, PerkinElmer Health Sciences, Inc.Inventors: Howard Cuckle, Kypros Nicolaides, Tarja Ahola, Leona Poon
-
Publication number: 20120135427Abstract: The present description relates to a method for determining the risk of a pregnant woman developing a hypertensive disorder, more specifically gestational hyper-tension or late onset preeclampsia. The present description provides methods useful for determining risk that a pregnant individual will develop a hypertensive disorder or condition of pregnancy, such as gestational hypertension, early preeclampsia, late preeclampsia and related disorders. Several useful combinations of biochemical markers and related clinical population studies are described herein. Additionally, it is proposed herein that certain sets of biochemical markers can be used to determine risk of multiple hypertensive disorders in a single screen. The biochemical markers are PlGF, Activin A and optionally P-Selectin.Type: ApplicationFiled: April 23, 2010Publication date: May 31, 2012Applicant: WALLAC OYInventors: Nicolaides Kypros, Tarja Ahola
-
Publication number: 20110294227Abstract: The present invention relates to a method for determining the risk of a pregnant woman developing pre-eclampsia. The method comprises i) determining the level of one or more biochemical markers in a sample obtained from a pregnant woman, and ii) comparing the level of the at least one biochemical marker in the sample with the level of the same biochemical marker in a control sample. A difference in the level of the biochemical marker in the sample relative to the control sample is indicative of an increased risk of developing pre-eclampsia. The isoform biochemical markers are preferably P1GF-2 and P1GF-3. The present invention relates also to a method for determining whether a pregnant woman has pre-eclampsia and as well as a kit for assessing the risk or presence of pre-eclampsia. In addition, the invention relates also to a computer program used in these determinations.Type: ApplicationFiled: November 20, 2009Publication date: December 1, 2011Applicants: PERKINELMER HEALTH SCIENCES, INC., WALLAC OY, NTD LABORATORIES, INC.Inventors: Tarja Ahola, Heini Frang, Teemu Korpimäki, Pertti Hurskainen, Mark N. Bobrow, Jonathan B. Carmichael
-
Publication number: 20100304412Abstract: The disclosure relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual has for developing pre-eclampsia based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers. The disclosure also relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual is carrying a fetus having a chromosomal abnormality based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers.Type: ApplicationFiled: January 26, 2009Publication date: December 2, 2010Inventors: Howard Cuckle, Kypros Nicolaides, Tarja Ahola, Leona Poon